Tamtuvetmab

• Target:

  NF-?B

• Related Pathways:

  NF-?B

• Bioactivity:

  Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1608122-71-9